Proteomic analysis in interstitial lung diseases: A review

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 5, 2009, Pages 470-478

  Rottoli, Paola ^a,d   Bargagli, Elena ^a   Landi, Claudia ^b   Magi, Barbara ^c  

^a Department of Clinical Medicine and Immunological Sciences ^*  (Italy)

^b Proteomics Laboratory   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Bronchoalveolar lavage; Interstitial lung diseases; Markers; Proteome; Serum

Indexed keywords

BIOLOGICAL MARKER;

BERYLLIOSIS; DISEASE COURSE; DISEASE SEVERITY; EXHAUST GAS; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL; LUNG LAVAGE; NONHUMAN; PNEUMOCONIOSIS; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; SARCOIDOSIS; SPUTUM ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYSTEMIC SCLEROSIS;

BLOOD PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE PROGRESSION; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; PROTEOMICS; SALIVA; SEVERITY OF ILLNESS INDEX;

EID: 68949187752     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32832ea4f2     Document Type: Review

References (66)

1. Magi B, Bargagli E, Bini L, Rottoli P. Protome analysis of bronchoalveolar lavage in lung diseases. Proteomics 2006; 6:6354-6369.
2. American Thoracic Society ATS, European Respiratory Society, ERS: International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165:227-304.
3. Govender P, Baugh JA, Pennington SR, et al. Role of proteomics in the investigation of pulmonary fibrosis without the need of an a priori hypothesis. Expert Rev Proteomics 2007; 4:79-88.
4. Hirsh J, Hansen KC, Burlingame AL, Matthay MA. Proteomics: current techniques and potential applications to lung diseases. Am J Physiol Lung Cell Mol Physiol 2004; 287:L1-L23.
5. Lindahl M, Ekstrom T, Sorensen J, Taggeson C. Two-dimensional protein patterns of BAL fluid from nonsmokers, smokers and subjects exposed to asbestos. Thorax 1996; 51:1028-1035.
6. Aliferis C, Caprioli RM. Genomics and proteomics of lung disease: conference summary. Am J Physiol Lung Cell Mol Physiol 2007; 293:L45-L51.
7. Levine SJ. Proteomics of lung cell biology and pulmonary disease. Expert Rev Respir Med 2007; 1:255-269.
8. Kriegova E, Melle C, Kolek V, et al. Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2006; 173:1145-1154.
9. Wattiez R, Hermans C, Cruyt C, et al. Human BAL fluid protein two dimensional database: study of ILD. Electrophoresis 2000; 21:2703-2712.
10. Magi B, Bini L, Perari MG, et al. Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis 2002; 23:3434-3444.
11. Rottoli P, Magi B, Perari MG, et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005; 5:1423-1430.
12. Rottoli P, Magi B, Cianti R, et al. Carbonylated proteins in BAL of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005; 5:2612-2618.
13. Bargagli E, Olivieri C, Prasse A, et al. Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Inflammation 2008; 31:351-354.
14. Silva E, Bourin S, Sabounchi-Schütt F, et al. A quantitative proteomic analysis of soluble bronchoalveolar fluid proteins from patients with sarcoidosis and chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2007; 24:24-32.
15. Fietta A, Bardoni A, Salvini R, et al. Analysis of BAL fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res Ther 2006; 8:R160.
16. Archimandriti DT, Dalavanga YA, Cianti R, et al. Protome analysis of BAL in individuals from Metsovo non occupationally exposed to asbestos. J Proteome Res 2009; 8:860-869.
17. Bai Y, Galetskiy D, Damoc E, et al. Lung alveolar proteomics of bronchoalveolar lavage from a pulmonary alveolar proteinosis patient using high-resolution FTICR mass spectrometry. Anal Bioanal Chem 2007; 389:1075-1085.
18. Passadore I, Iadarola P, Di Poto C, et al. 2-DE and LC-MS/MS for a comparative proteomic analysis of BALf from patients with different subsets of inflammatory myopathies. J Proteome Res 2009; 8:2331-2340.
19. Takahashi T, Wada I, Ohtsuka Y, et al. Autoantibody to alanyl-tRNA synthe-tase in patients with idiopathic pulmonary fibrosis. Respirology 2007; 12:642-653.
20. Sabounchi-Schütt F, Mikko M, Eklund A, et al. Serum protein pattern in sarcoidosis analysed by a proteomics approach. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:182-190.
21. Bons JA, Drent M, Bouwman FG, et al. Potential biomarkers for diagnosis of sarcoidosis using proteomics in serum. Respir Med 2007; 101:1687-1695.
22. Wang SX, Zhao XF, Wei MT, et al. Screening of serum biomarkers and establishment of a decision tree in silica-exposed populations by surface-enhanced laser desorption ionization time-of-fly mass spectrometry. J Occup Environ Med 2007; 49:764-770.
23. Giusti L, Bazzichi L, Baldini C, etal. Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. J Rheumatol 2007; 34:2063-2069.
24. Peluso G, De Santis M, Inzitari R, et al. Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. Arthritis Rheum 2007; 56:2216-2222.
25. Bogatkevich GS, Ludwicka-Bradley A, Singleton CB, et al. Proteomic analysis of CTGF-activated lungfibroblasts: identification of IQGAP1 as a key player in lung fibroblast migration. Am J Physiol Lung Cell Mol Physiol 2008; 295: L603-L611.
26. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, et al. Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21. Eur Respir J 2007; 29:1082-1093.
27. Larsen K, Malmstrom J, Wildt M, etal. Functional and phenotypical comparison of myofibroblats derived from biopsies and bronchoalveolar lavage in mild asthma and scleroderma. Respir Res 2006; 23:7-11.
28. Aden N, Shiwen X, Aden D, et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford) 2008; 47:1754-1760.
29. Wilkins MR, Appel RD, Van Eyk JE, etal. Guidelines for the next 10 years of proteomics. Proteomics 2006; 6:4-8.
30. Rottoli P. Proteomics in BAL: improved technique may yield more fish. Revista Portuguesa Pneumol 2007; 13:41-45.
31. Crameri R. Potential of proteomics and peptidomics for allergy and asthma research. Allergy 2005; 60:1227-1237.
32. Wattiez R, Falmagne P. Proteomics of BAL fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815:169-178.
33. Houtman R, van den Worm E. Asthma, the ugly duckling of lung disease proteomics? J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815: 285-294.
34. Bowler RP, Ellison MC, Reisdorph N. Proteomics in pulmonary medicine. Chest 2006; 130:567-574.
35. Ware LB, Matthay MA. Beyond fishing: the role of discovery proteomics in mechanistic lung research. Am J Physiol Lung Cell Mol Physiol 2009; 296:L12-L13.
36. Li SJ, Peng M, Li H, etal. Sys-BodyFluid: a systematical database for human body fluid proteome research. Nucl Acids Res 2009; 37:907-912.
37. Plymoth A, Löfdahl CG, Ekberg-Jansson A, et al. Protein expression patterns associated with progression of chronic obstructive pulmonary disease in bronchoalveolar lavage of smokers. Clin Chem 2007; 53:636-644.
38. Bowler RP, Duda B, Chan ED, et al. Proteomic analysis of pulmonary edema fluid and plasma in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286:L1095-L1104.
39. Leroy B, Falmagne P, Wattiez R. Sample preparation of bronchoalveolar lavage fluid. Methods Mol Biol 2008; 425:67-75.
40. Noel-Georis I, Bernard A, Falmagne P, Wattiez R. Database of bronchoalveolar lavage fluid proteins. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 771:221-236.
41. Plymoth A, Lofdahl CG, Ekberg-Jansson A, et al. Human bronchoalveolar lavage: biofluid analysis with special emphasis on sample preparation. Proteomics 2003; 3:962-972.
42. Nicholas B, Skipp P, Mould R, et al. Shotgun proteomic analysis of human-induced sputum. Proteomics 2006; 6:4390-4401.
43. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163:1693-1722.
44. Rao PV, Reddy AP, Lu X, etal. Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res 2009; 8:239-245.
45. Hu S, Arellano M, Boontheung P, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008; 14:6246-6252.
46. Dowling P, Wormald R, Meleady P, et al. Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis. J Proteomics 2008; 71:168-175.
47. Messana I, Inzitari R, Fanali C, etal. Facts and artifacts in proteomics of body fluids. What proteomics of saliva is telling us? J Sep Sci 2008; 31:1948-1963.
48. Candiano G, Bruschi M, Pedemonte N, etal. Proteomic analysis of the airway surface liquid: modulation by proinflammatory cytokines. Am J Physiol Lung Cell Mol Physiol 2007; 292:185-198.
49. Kypreou KP, Kavvadas P, Karamessinis P, et al. Altered expression of calreticulin during the development of fibrosis. Proteomics 2008; 8:2407-2419.
50. Hoving S, Voshol H, Van Oostrum J. Towards high performance two dimensional gel electrophoresis using ultrazoom gels. Electrophoresis 2000; 21:2617-2621.
51. Zuo X, Speicher DW. Comprehensive analysis of complex proteomes using microscale solution isoelectrofocusing prior to narrow pH range two-dimensional electrophoresis. Proteomics 2002; 2:58-68.
52. Carrette O, Burkhard PR, Sanchez JF, Hochstrasser DF. State of the art 2DE: a key tool of proteomics research. Nat Protoc 2006; 1:812-823.
53. Bai Y, Galetskiy D, Damoc E, et al. High resolution mass spectrometric alveolar proteomics: identification of surfactant protein SP-A and SP-D modifications in proteinosis and cystic fibrosis patients. Proteomics 2004; 4:2300-2309.
54. Marko-Varga G, Lindberg H, et al. Discovery of biomarkers candidates within disease by protein profiling: principles and concepts. J Proteome Res 2005; 4:1200-1212.
55. Qian WJ, Jacobs JM, Liu T, et al. Advances and challenges in liquid chro-matography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics 2006; 5:1727-1744.
56. Plymoth A, Jung Z, Lofdahl CG, et al. Rapid proteome analysis of BAL samples of life long smokers and never smokers by micro-scale liquid chromatography and MS. Clin Chem 2006; 52:671-679.
57. Gray RD, MacGregor G, Noble D, et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008; 178:444-452.
58. Merkel D, Rist W, Seither P, et al. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005; 5:2972-2980.
59. Chen ES, Moller DR. Expression profiling in granulomatous lung disease. Proc AmThorac Soc 2007; 4:101-107.
60. Lorenz E, Muhlebah MS, Tessier PA, et al. Different expression ratio of S100 A8-A9 and S100 A12 in acute an chronic lung diseases. Respir Med 2008; 102:567-573.
61. Guo Y, Fu Z, Van Eyk JE. A proteomic primer for clinician. Proc Am Thorac Soc 2007; 4:9-17.
62. Adkins JN, Varnum SM, Auberry KJ, et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002; 1:947-955.
63. Link AJ, Eng J, Schieltz DM, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999; 17:676-682.
64. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005; 563:23-60.
65. Song Z, Marzilli L, Greenlee BM, etal. Mycobacterium catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005; 201:755-767.
66. Fumagalli M, Dolcini L, Sala A, et al. Proteomic analysis of exhaled breath condensate from single patients with pulmonary emphysema associated to alpha1-antitrypsin deficiency. J Proteomics 2008; 71:211-221.